MAP1LC3A and juvenile idiopathic arthritis: As the initial screening proved to be promising for Adalimumab peptides HC3 and LC3, a larger scale testing was initiated using a total of 29 sera from Adalimumab treated JIA patients and eight non-treated JIA patients as controls.